written on 24.04.2014
pt:
Tags:
,

Celgene beats on earnings, despite decline in U.S. Revlimid sales

TAGS: ,

Celgene's earnings topped expectations for the first quarter, as its blood-cancer drug Revlimid continued to deliver double-digit sales growth.

Latest Report